Fig. 2: Anti-PD1-mIL12mut2 preferentially binds to tumor-infiltrating PD-1+CD8+T cells. | Nature Communications

Fig. 2: Anti-PD1-mIL12mut2 preferentially binds to tumor-infiltrating PD-1+CD8+T cells.

From: Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses

Fig. 2

a The PD-1 expression on CD8+T cells in different tissues from MC38 tumor-bearing mice (n = 6 mice). b The PD-1 expression on CD4+T cells, CD8+T cells, or NK cells in MC38 tumor (n = 4 mice). c HEK cells were incubated with mIL12wt, mIL12mut1, or mIL12mut2 in vitro. Protein binding to HEK cells was detected by flow cytometric analysis (n = 2). d Schematic diagram of αPD1-mIL12mut2. e Single-cell suspension of MC38 tumor tissue (n = 4 mice) was incubated with αEGFR-mIL12mut2 or αPD1-mIL12mut2 in vitro. Protein binding to CD4+T cells, CD8+T cells, or NK cells was detected by flow cytometric analysis. f MC38 tumor-bearing mice (n = 5) were intraperitoneally injected with 20 μg αPD1-mIL12mut2 and sacrificed 24 h after treatment. Mice tissues were collected and homogenized. The concentration of fusion protein in the supernatant was measured and normalized using ELISA. MFI mean fluorescence intensity. All data are shown as mean ± SD from two to three independent experiments. The P value was determined by one-way (a, b), two-way ANOVA (e) or unpaired t test (f).

Back to article page